Navigation Links
AviaraDx Presents at 2007 BIOCOM Investor Conference

Newly formed molecular diagnostic company launches two oncology tests

SAN DIEGO, Oct. 5 /PRNewswire/ -- AviaraDx, Inc., announced today that the company is scheduled to provide a corporate overview of its molecular diagnostic test offerings and development programs at the 2007 BIOCOM Investor Conference. The presentation is scheduled for Thursday, November 1st, at 2:30 p.m. in the Rancho Santa Fe ballroom of the San Diego Marriott Del Mar Hotel, 11966 El Camino Real, San Diego, CA 92130.

About AviaraDx, Inc.

AviaraDx discovers, develops, and commercializes new molecular diagnostic tests in oncology, enabling physicians to personalize cancer treatment through better understanding of the molecular biology underlying a patient's tumor. Our tests improve the classification of cancer, support physicians to provide their patients with a more specific prognosis or individual risk assessment, and will provide information critical to predict treatment response to a given therapeutic regimen. AviaraDx offers diagnostic tests to qualified physicians or laboratories through its CAP-certified CLIA laboratory service operations. The company's first diagnostic test offerings are based on its proprietary technologies for the molecular classification of metastatic cancer, CancerTYPE ID(TM), and its H/I(TM) (HOXB13/IL17BR) test to assess risk of recurrence and response to endocrine therapy in certain breast cancer patients.


Antonius Schuh, Ph.D.

Chief Executive Officer

+1 (760) 579 0500

SOURCE AviaraDx, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
3. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
4. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
5. Monogram Presents Results of First ETag Breast Cancer Studies
6. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
7. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
8. International Conference On Malaria - Laveran To Genomics
9. African Conference to Combat AIDS
10. International conference on Ayurveda to be held on Kerala
11. 5th European Breast Cancer Conference Talks about Everything from Patient to Oncologist
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: